Courtesy- Picserver
Leucine Rich Bio, a genomics company, has partnered with Vittarthaa Life Sciences, a drug discovery and development company, focusing on identifying unmet clinical needs to develop pharmaceutical molecules.
The Bengaluru-based Leucine has developed analysis and interpretation pipelines for next generation sequencing and microarray data.
Apart from that, the company has provided customized meta-analysis of publicly available data to cater to its client base which is spread across the globe. With strong systems biology, molecular biology and genomics background, the company can provide an umbrella of bio-informatics and other data solutions to its clients.
For Vittartha, all research programs are based on integrated approach towards target-based discovery strategies and phenotypic screening for end-point evaluation. It is also focused on innovative discovery and development approaches for progressing molecules into market.
The discovery programme devises multi-parametric, phenotypic panel assay screening efficacy that are target based and de-risk toxicity at early stages. The company engages the customer at early stages of drug development providing suitable platforms for mapping the molecular mechanisms that enable to create program objective, target product profile and outline milestones decisions.
Both the companies have announced collaboration in order to provide pharmaceutical, nutraceuticals and biotechnology companies a combined portfolio of research solutions under one platform.
